<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC7102518/results/search/country/results.xml">
  <result pre="K.rplemper@gsu.edu⁎[], ⁎Reprint requests: Richard K. Plemper, Institute for Biomedical Sciences," exact="Georgia" post="State University, Atlanta, GA 30303. rplemper@gsu.edu pmc-release: 2020-2-2ppub: 2020-6epub:"/>
  <result pre="other influenza drug classes in circulating viruses, many countries including" exact="the United States" post="and China have banned their use in agriculture. In"/>
  <result pre="influenza drug classes in circulating viruses, many countries including the" exact="United States" post="and China have banned their use in agriculture. In"/>
  <result pre="in circulating viruses, many countries including the United States and" exact="China" post="have banned their use in agriculture. In the past"/>
  <result pre="due to high level of preexisting resistance †conditionally approved in" exact="Japan" post="against emerging influenza viruses resistant to other antivirals Neuraminidase"/>
  <result pre="founding member of the PA endonuclease inhibitor class Licensed in" exact="Japan" post="and the United States since 2018, baloxavir marboxil (Fig"/>
  <result pre="of the PA endonuclease inhibitor class Licensed in Japan and" exact="the United States" post="since 2018, baloxavir marboxil (Fig 1) is the first"/>
  <result pre="the PA endonuclease inhibitor class Licensed in Japan and the" exact="United States" post="since 2018, baloxavir marboxil (Fig 1) is the first"/>
  <result pre="through mice.85,86 A small percentage of influenza viruses circulating in" exact="the United States" post="in the 2016/2017 and 2017/2018 seasons, and thus prior"/>
  <result pre="mice.85,86 A small percentage of influenza viruses circulating in the" exact="United States" post="in the 2016/2017 and 2017/2018 seasons, and thus prior"/>
  <result pre="close to the approved human dose.99,102 Although conditionally licensed in" exact="Japan" post="for the treatment of pathogenic influenza viruses resistant to"/>
  <result pre="with proteolytic cleavageJ Gen Virol71Pt 51990118911971693166 3GartenR.BlantonL.ElalA.I.A.AlabiN.BarnesJ.BiggerstaffM.Update: influenza activity in" exact="the United States" post="during the 2017-18 season and composition of the 2018-19"/>
  <result pre="proteolytic cleavageJ Gen Virol71Pt 51990118911971693166 3GartenR.BlantonL.ElalA.I.A.AlabiN.BarnesJ.BiggerstaffM.Update: influenza activity in the" exact="United States" post="during the 2017-18 season and composition of the 2018-19"/>
  <result pre="Infect Dis2212020637031419295 87GubarevaL.V.MishinV.P.PatelM.C.Assessing baloxavir susceptibility of influenza viruses circulating in" exact="the United States" post="during the 2016/17 and 2017/18 seasonsEuro Surveill2420191800666 88KoszalkaP.TilmanisD.RoeM.VijaykrishnaD.HurtA.C.Baloxavir marboxil"/>
  <result pre="Dis2212020637031419295 87GubarevaL.V.MishinV.P.PatelM.C.Assessing baloxavir susceptibility of influenza viruses circulating in the" exact="United States" post="during the 2016/17 and 2017/18 seasonsEuro Surveill2420191800666 88KoszalkaP.TilmanisD.RoeM.VijaykrishnaD.HurtA.C.Baloxavir marboxil"/>
 </snippets>
</snippetsTree>
